Phair JP - Search Results

1

Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.

Tarwater PM, Gallant JE, Mellors JW, Gore ME, Phair JP, Detels R, Margolick JB, Muñoz A. Tarwater PM, et al. Among authors: phair jp. AIDS. 2004 Dec 3;18(18):2419-23. AIDS. 2004. PMID: 15622318

2

Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy.

Gange SJ, Lau B, Phair J, Riddler SA, Detels R, Margolick JB. Gange SJ, et al. AIDS. 2003 Jan 3;17(1):119-21. doi: 10.1097/00002030-200301030-00016. AIDS. 2003. PMID: 12478077 No abstract available.

3

Virologic and immunologic values allowing safe deferral of antiretroviral therapy.

Phair JP, Mellors JW, Detels R, Margolick JB, Muñoz A. Phair JP, et al. AIDS. 2002 Dec 6;16(18):2455-9. doi: 10.1097/00002030-200212060-00011. AIDS. 2002. PMID: 12461420

4

When to initiate highly active antiretroviral therapy: a cohort approach.

Ahdieh-Grant L, Yamashita TE, Phair JP, Detels R, Wolinsky SM, Margolick JB, Rinaldo CR, Jacobson LP. Ahdieh-Grant L, et al. Among authors: phair jp. Am J Epidemiol. 2003 Apr 15;157(8):738-46. doi: 10.1093/aje/kwg036. Am J Epidemiol. 2003. PMID: 12697578

5

Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men.

Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB. Lau B, et al. Among authors: phair jp. AIDS. 2003 Sep 26;17(14):2035-44. doi: 10.1097/00002030-200309260-00004. AIDS. 2003. PMID: 14502006

6

Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003.

Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, Riddler SA, Williams CM, Phair JP; Multicenter AIDS Cohort Study. Seaberg EC, et al. Among authors: phair jp. AIDS. 2005 Jun 10;19(9):953-60. doi: 10.1097/01.aids.0000171410.76607.f8. AIDS. 2005. PMID: 15905677

7

Thrush and fever as markers of immune competence in the era of highly active antiretroviral therapy.

Skolasky RL, Phair J, Detels R, Riddler S, Margolick J, Jacobson LP. Skolasky RL, et al. AIDS Res Hum Retroviruses. 2001 Sep 20;17(14):1311-6. doi: 10.1089/08892220152596551. AIDS Res Hum Retroviruses. 2001. PMID: 11602040

8

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A. Jacobson LP, et al. Am J Epidemiol. 2002 Apr 15;155(8):760-70. doi: 10.1093/aje/155.8.760. Am J Epidemiol. 2002. PMID: 11943695

9

Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals.

Wada N, Jacobson LP, Cohen M, French A, Phair J, Muñoz A. Wada N, et al. AIDS. 2014 Jan 14;28(2):257-65. doi: 10.1097/QAD.0000000000000078. AIDS. 2014. PMID: 24105030 Free PMC article.

10

Increases in duration of first highly active antiretroviral therapy over time (1996-2009) and associated factors in the Multicenter AIDS Cohort Study.

Slama L, Li X, Brown T, Jacobson LP, Pialoux G, Macatangay B, Bolan RK, Phair J, Palella FJ Jr; Multicenter AIDS cohort Study. Slama L, et al. J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):57-64. doi: 10.1097/QAI.0b013e3182a99a0d. J Acquir Immune Defic Syndr. 2014. PMID: 24419062 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

302 results

Search Page

Filters